Cargando…
Novel TGF-β inhibitors ready for prime time in onco-immunology
Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283641/ https://www.ncbi.nlm.nih.gov/pubmed/28197376 http://dx.doi.org/10.1080/2162402X.2016.1257453 |
| _version_ | 1782503526431195136 |
|---|---|
| author | de Gramont, Armand Faivre, Sandrine Raymond, Eric |
| author_facet | de Gramont, Armand Faivre, Sandrine Raymond, Eric |
| author_sort | de Gramont, Armand |
| collection | PubMed |
| description | Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees. |
| format | Online Article Text |
| id | pubmed-5283641 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Taylor & Francis |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-52836412017-02-14 Novel TGF-β inhibitors ready for prime time in onco-immunology de Gramont, Armand Faivre, Sandrine Raymond, Eric Oncoimmunology Point of View Transforming Growth Factor (TGF)-β inhibitors have been in development for decades with the outmost results of being promising candidates. From the latest clinical results at the 2016 ASCO meeting converging evidences suggest that we have moved from promising to effective drug nominees. Taylor & Francis 2016-12-07 /pmc/articles/PMC5283641/ /pubmed/28197376 http://dx.doi.org/10.1080/2162402X.2016.1257453 Text en © 2017 The Author(s). © Armand de Gramont, Sandrine Faivre, and Eric Raymond. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. |
| spellingShingle | Point of View de Gramont, Armand Faivre, Sandrine Raymond, Eric Novel TGF-β inhibitors ready for prime time in onco-immunology |
| title | Novel TGF-β inhibitors ready for prime time in onco-immunology |
| title_full | Novel TGF-β inhibitors ready for prime time in onco-immunology |
| title_fullStr | Novel TGF-β inhibitors ready for prime time in onco-immunology |
| title_full_unstemmed | Novel TGF-β inhibitors ready for prime time in onco-immunology |
| title_short | Novel TGF-β inhibitors ready for prime time in onco-immunology |
| title_sort | novel tgf-β inhibitors ready for prime time in onco-immunology |
| topic | Point of View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5283641/ https://www.ncbi.nlm.nih.gov/pubmed/28197376 http://dx.doi.org/10.1080/2162402X.2016.1257453 |
| work_keys_str_mv | AT degramontarmand noveltgfbinhibitorsreadyforprimetimeinoncoimmunology AT faivresandrine noveltgfbinhibitorsreadyforprimetimeinoncoimmunology AT raymonderic noveltgfbinhibitorsreadyforprimetimeinoncoimmunology |